Browse Category

NASDAQ:CRNX News 29 September 2025 - 7 January 2026

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved acromegaly drug. Crinetics said it generated preliminary, unaudited net product revenue of more than $5 million from PALSONIFY in the fourth quarter of 2025, with more than 200 enrollment forms and over 125 unique prescribers by the end of December. It also posted Phase 2 results for atumelnant in congenital adrenal hyperplasia (CAH), reporting a 67% mean reduction in androstenedione
7 January 2026
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) stock slid sharply on Thursday, December 18, 2025, after a regulatory filing revealed a leadership transition involving the company’s Chief Medical and Development Officer. In trading, CRNX fell roughly 8% to around the mid‑$40s, with the day’s range stretching from the low‑$40s to the high‑$40s as investors digested the update. Investing.com For a biotech stock—especially one in the middle of a major product launch and multiple late‑stage trials—management continuity matters. But so do fundamentals: Crinetics is no longer “just” a clinical-stage story. It recently reached a pivotal milestone with its first FDA-approved product, and its
18 December 2025
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Wall Street’s Winning Streak and Market Backdrop Even as a possible U.S. government shutdown loomed on Capitol Hill, Wall Street managed a modest rise on September 29, 2025. The tech-heavy Nasdaq Composite climbed about 0.5% on the day reuters.com, with investors largely shrugging off fiscal uncertainty. “Investors are clinging to the positives,” noted one strategist, citing hopes of future interest rate cuts and solid economic data reuters.com. Against this cautiously optimistic backdrop, a handful of individual stocks delivered outsized gains thanks to company-specific catalysts – from blockbuster M&A deals to drug approvals and speculative frenzies. Below, we break down the

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop